During 2018 Q4 the big money sentiment decreased to 0.93. That’s change of 0.56, from 2018Q3’s 1.49. 25 investors sold all, 74 reduced holdings as LOXO ratio turned negative. 59 grew stakes while 33 funds amassed stakes. Funds hold 28.12 million shares thus 0.59% less from 2018Q3’s 28.29 million shares. First Personal Financial Svcs invested 0% of its capital in Loxo Oncology, Inc. (NASDAQ:LOXO). Manufacturers Life Ins The, Ontario – Canada-based fund reported 18,317 shs. Venbio Select Advisor Lc holds 2.72% or 325,000 shs. Dekabank Deutsche Girozentrale, Germany-based fund reported 11,380 shs. Panagora Asset Management Inc holds 0.01% or 22,262 shs. California Employees Retirement reported 39,872 shs or 0.01% of all its holdings. Neuberger Berman Grp Inc Lc holds 0% in Loxo Oncology, Inc. (NASDAQ:LOXO) or 2,500 shs. Columbus Circle Investors owns 8,776 shs or 0.03% of their US capital. Segall Bryant Hamill Limited Liability reported 4,493 shs stake. Point72 Asset Mgmt LP holds 0.68% or 990,719 shs in its capital. Zurcher Kantonalbank (Zurich Cantonalbank) holds 0% of its capital in Loxo Oncology, Inc. (NASDAQ:LOXO) for 1,477 shs. Daiwa Grp Incorporated holds 0% or 165 shs. First Quadrant Lp Ca owns 351 shs or 0% of their US capital. Vanguard Group Inc Inc holds 2.79M shs or 0.02% of its capital. First Mercantile Trust Company invested 0.02% in Loxo Oncology, Inc. (NASDAQ:LOXO).

LOXO had 4 selling transactions and 1 buy since November 26, 2018. This’s net activity of $7.11 million. 9,000 shs were sold by Van Naarden Jacob, worth $1.22M on Monday, December 10. Bilenker Joshua H. sold $2.71M worth of stock. Burstein Jennifer sold $338,875 worth of stock.

Driehaus Capital Management Llc reduced its stake by 9.74% in Loxo Oncology Inc (LOXO), according to 2018Q4 SEC filling. By selling 27,425 shares Driehaus Capital Management Llc made the stock with 0.00%. The health care company reported $35.62M value for the 2018Q4. Now the hedge fund is holding 254,274 shares, compared to the 281,699 from the previous quarter. $7.22 billion is the market cap of Loxo Oncology Inc. $234.66 was the last price.Since April 3, 2018 it’s 0.00% down thus . LOXO underperformed the S&P 500 by 4.37%.

Driehaus Capital Management Llc manages about $12.71 billion and $2.34 billion US Long portfolio. It rose its stake in Vericel Corp by 484,840 shares to 1.10M shares, valued at $19.08 million in 2018Q4, according to the filing. Driehaus Capital Management Llc has risen its stake in Alibaba Group Holding (NYSE:BABA) and also increased its holding in Kratos Defense & Security (NASDAQ:KTOS) by 401,165 shares in the quarter, for a total of 1.06 million shares.

For more Loxo Oncology, Inc. (NASDAQ:LOXO) news published recently go to: Nasdaq.com, Nasdaq.com, Nasdaq.com, Nasdaq.com or Nasdaq.com. The titles are as follows: “Health Care Sector Update for 01/07/2019: LOXO, LLY, MYND, AXSM, JNJ, PFE, MRK, ABT, AMGN – Nasdaq” published on January 07, 2019, “Bayer Obtains Full Rights to Vitrakvi From Lilly’s Loxo – Nasdaq” on February 19, 2019, “Lilly (LLY) Signs New Immunology Deal With Private Biotech – Nasdaq” with a publish date: March 27, 2019, “3 Small-Cap Biotech Stocks to Watch Now – Nasdaq” and the last “Pharma Stock Roundup: Lilly to Buy Loxo for $8B, M&A in Focus at JP Morgan Meet – Nasdaq” with publication date: January 11, 2019.

Loxo Oncology, Inc. (NASDAQ:LOXO) Ratings Coverage

A total of 4 analysts rate Loxo Oncology (NASDAQ:LOXO) as follows: 4 “Buy”, 0 “Hold” and 0 “Sell”. Тherefore 100% are bullish. (NASDAQ:LOXO) has 7 ratings reports on Apr 3, 2019 according to StockzIntelligence. The company rating was maintained by JMP Securities on Tuesday, November 27. On Thursday, October 11 the stock has “Overweight” rating by Morgan Stanley. On Wednesday, October 24 the firm has “Buy” rating given by Citigroup. On Tuesday, November 13 the rating was maintained by JMP Securities with “Market Outperform”. On Friday, November 16 the rating was maintained by Citigroup with “Buy”.